Tibotec’s Etravirine NNRTI For HIV NDA Has Jan. 18 Action Date
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J subsidiary's non-nucleoside reverse transcriptase inhibitor was granted priority review by FDA.
You may also be interested in...
J&J’s Intelence Approved For HIV Treatment In NNRTI-Resistant Patients
Johnson & Johnson’s Tibotec unit prices etravirine at wholesale acquisition cost of $5.45, firm tells “The Pink Sheet” DAILY.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.